o continuing to work with FDA as we prepare a number of clinical studies for disease states with high unmet clinical needs." Robert Sexauer, EVP of Clinical Development stated "We can now begin to move forward with our plans for in- human clinical studies such as lower limb ischemia by applying to Institutional Revie